Inventor · disambiguated record
Paul Foster
Also filed as: FOSTER PAUL · FOSTER PAUL STEPHEN
6 granted patents·20 pending applications·24 citations·filing 2008–2025
78Inventor score
Files withXENCOR INC14CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC3NOVARTIS AG3CENTRAL ADELAIDE LOCAL HEALTH NEWORK INC1Central Adelaide Local Health Network1
Top patents by PatentIndex Score
26 records- 0195US11225521B2Heterodimeric antibodies that bind somatostatin receptor 2XENCOR INC·Filed 2019·Granted Jan 18, 2022·11 cites·23 claims
- 0292US10316088B2Heterodimeric antibodies that bind somatostatin receptor 2XENCOR INC·Filed 2017·Granted Jun 11, 2019·11 cites·4 claims
- 0377US12054545B2Heterodimeric antibodies that bind somatostatin receptor 2XENCOR INC·Filed 2021·Granted Aug 6, 2024·0 cites·6 claims
- 0477US2024076393A1Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptorCENTRAL ADELAIDE LOCAL HEALTH NETWORK INC·Filed 2023·Application pending·0 cites
- 0573US11365256B2Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseasesXENCOR INC·Filed 2017·Granted Jun 21, 2022·2 cites·25 claims
- 0672US12509518B2Methods and compositions for inhibiting CD32B expressing cells in IgG4-related diseasesXENCOR INC·Filed 2022·Granted Dec 30, 2025·0 cites·12 claims
- 0772US2025115667A1Dosing of a bispecific antibody that binds pd1 and ctla4XENCOR INC·Filed 2024·Application pending·0 cites
- 0871US2010260744A1Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptorMEDVET SCIENCE PTY LTD·Filed 2008·Application pending·0 cites
- 0967US2025340650A1Methods and compositions for inhibiting cd32b expressing cells in igg4-related diseasesXENCOR INC·Filed 2025·Application pending·0 cites
- 1065US2021317218A1Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptorCENTRAL ADELAIDE LOCAL HEALTH NETWORK INC·Filed 2021·Application pending·0 cites
- 1159US2018155435A1Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptorCentral Adelaide Local Health Network·Filed 2017·Application pending·0 cites
- 1259US2023074793A1Treatment with a bispecific antibody that binds ctla4 and pd1XENCOR INC·Filed 2022·Application pending·0 cites
- 1359US2015232564A1Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptorCENTRAL ADELAIDE LOCAL HEALTH NEWORK INC·Filed 2015·Application pending·0 cites
- 1458US2020055943A1Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptorCENTRAL ADELAIDE LOCAL HEALTH NETWORK INC·Filed 2019·Application pending·0 cites
- 1557US2014023658A1Regulating il-4 and il-3 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptorLOPEZ ANGEL·Filed 2013·Application pending·0 cites
- 1656US2021079094A1Dosing of a bispecific antibody that binds pd1 and ctla4XENCOR INC·Filed 2020·Application pending·0 cites
- 1752US2024262907A1Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)XENCOR INC·Filed 2021·Application pending·0 cites
- 1850US2021147561A1Bispecific antibodies that bind cd123 and cd3XENCOR INC·Filed 2020·Application pending·0 cites
- 1948US2021095027A1Bispecific antibodies that bind cd20 and cd3XENCOR INC·Filed 2020·Application pending·0 cites
- 2044US2017349660A1Bispecific antibodies that bind cd123 and cd3XENCOR INC·Filed 2017·Application pending·0 cites
- 2140US2017349657A1Bispecific antibodies that bind cd20 and cd3XENCOR INC·Filed 2017·Application pending·0 cites
- 2240US2021230281A1Dosing of a bispecific antibody that bind cd123 and cd3NOVARTIS AG·Filed 2019·Application pending·0 cites
- 2339US8288358B2Therapeutic targets and moleculesFOSTER PAUL STEPHEN·Filed 2008·Granted Oct 16, 2012·0 cites·5 claims
- 2434US2021205449A1Dosing of a bispecific antibody that bind cd123 and cd3NOVARTIS AG·Filed 2019·Application pending·0 cites
- 2533US2020181274A1Bispecific antibodies that bind cd 123 cd3NOVARTIS AG·Filed 2018·Application pending·0 cites
- 2628US2013309238A1Signal transduction pathway modulationMATTES JOERG·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Paul Foster files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →